---
layout: post
title: "百诚医药：bios-0618等5个创新药属于公司自主研发项目"
date: 2022-05-25 11:40:57 +0800
categories: shanghaizhengquanbao·zhongguozhengquanwang
tags: 上海证券报·中国证券网新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.301096" data-code="301096|0|2" data-code2="301096|0|80|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.301096&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 301096_0" data-code="K 301096|0|2" data-code2="K 301096|0|80|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>上证报中国证券网讯百诚医药25日在互动平台上回答投资者提问时表示，bios-0618等5个创新药属于公司自主研发项目。<br /></p><p class="em_media">（文章来源：上海证券报·中国证券网）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202205252391310236>

[返回上海证券报·中国证券网新闻](//finews.withounder.com/category/shanghaizhengquanbao·zhongguozhengquanwang.html)｜[返回首页](//finews.withounder.com/)